Myriad Genetics touted three studies at the meeting of the American College of Rheumatology in San Francisco showing that its Vectra DA diagnostic for measuring the severity of rheumatoid arthritis can help guide patient selection for biologic or nonbiologic drugs by predicting their response to the various therapies and treatment strategies.
SetPoint Medical has an ambitious aim to use bioelectronics to treat inflammatory ailments and an equally impressive line-up of venture investors--including several strategic ones. Now it's added $15 million to a Series C round that originally closed in August 2013 to hit a total of $43 million. The financing will go to further advance its neuromodulation device in clinical studies to treat rheumatoid arthritis and Crohn's Disease.
Drugmakers are eager to jump on the rheumatoid arthritis (RA) bandwagon, concentrating on tried-and-true treatments to bring in sales or developing new therapies to stave off looming biosimilars competition. But the meds come with their own set of safety issues, as both TNF-alpha treatments and non-TNF alpha drugs continue to generate troubling side effect reports.
The cost-effectiveness watchdogs at the National Institute for Health and Care Excellence have put their money behind biosimilars. Remicade biosimilars, to be exact, in new guidance for treating rheumatoid arthritis.
SetPoint Medical is starting a clinical trial to treat Crohn's disease patients with its implantable neuromodulation device. The startup previously reported a positive pilot study of the device to treat rheumatoid arthritis.
Researchers have identified a new biomarker for rheumatoid arthritis that could help with earlier diagnosis and treatment.
A novel biomarker could make it easier for physicians to diagnose rheumatoid arthritis early, thereby improving patients' prospects. The best results come when conventional antibody testing is combined with the new biomarker.
Myriad Genetics paid $270 million for Crescendo Bioscience in February, and now a new study affirms the clinical viability of Crescendo's Vectra DA, a protein-based test designed to assess a patient's rheumatoid arthritis disease progression and activity.
Inova Diagnostics once again has its sights on rheumatoid arthritis-detecting technology, this week acquiring a novel platform developed at Hasselt University designed to identify autoantibody biomarkers for the debilitating condition.
With sales of eye drug Eylea growing at breakneck pace and a couple of promising candidates in its pipeline, Regeneron needs some more space.